LAPTM4B facilitates late endosomal ceramide export to control cell death pathways

Nature Chemical Biology

Volumn 11, Issue 10, 2015, Pages 799-806

  Blom, Tomas ^a,b   Li, Shiqian ^a,b   Dichlberger, Andrea ^a,b   Bäck, Nils ^a   Kim, Young Ah ^c   Loizides Mangold, Ursula ^d   Riezman, Howard ^d   Bittman, Robert ^c   Ikonen, Elina ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACID CERAMIDASE; ANTIINFECTIVE AGENT; CASPASE 3; CERAMIDE; LYSOSOME ASSOCIATED PROTEIN TRANSMEMBRANE 4B; MEMBRANE PROTEIN; SPHINGOLIPID; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; LAPTM4B PROTEIN, HUMAN; ONCOPROTEIN; PACLITAXEL; PROTEIN BINDING; SMALL INTERFERING RNA; SPHINGOMYELIN;

APOPTOSIS; ARTICLE; CATABOLISM; CELL COMPARTMENTALIZATION; CELL DEATH; CELL ORGANELLE; CONTROLLED STUDY; ENDOSOME; ENZYME MECHANISM; GENE SILENCING; LYSOSOME; LYSOSOME MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; DRUG EFFECTS; GENETICS; HUMAN; INTRACELLULAR MEMBRANE; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CERAMIDES; ENDOSOMES; GENE SILENCING; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE PROTEINS; ONCOGENE PROTEINS; PACLITAXEL; PROTEIN BINDING; RNA, SMALL INTERFERING; SPHINGOMYELINS;

EID: 84941879088     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1889     Document Type: Article

References (51)

1. Schulze, H. & Sandhoff, K. Sphingolipids and lysosomal pathologies. Biochim. Biophys. Acta 1841, 799-810 (2014).
2. Kolter, T. & Sandhoff, K. Lysosomal degradation of membrane lipids. FEBS Lett. 584, 1700-1712 (2010).
3. Lloyd-Evans, E. et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat. Med. 14, 1247-1255 (2008).
4. Speak, A.O. et al. Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1. Blood 123, 51-60 (2014).
5. Blom, T., Li, Z., Bittman, R., Somerharju, P. & Ikonen, E. Tracking sphingosine metabolism and transport in sphingolipidoses: NPC1 deficiency as a test case. Traffic 13, 1234-1243 (2012).
6. Hanada, K. et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426, 803-809 (2003).
7. Truman, J.-P., García-Barros, M., Obeid, L.M. & Hannun, Y.A. Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim. Biophys. Acta 1841, 1174-1188 (2014).
8. Park, J.-W., Park, W.-J. & Futerman, A.H. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim. Biophys. Acta 1841, 671-681 (2014).
9. Henry, B., Möller, C., Dimanche-Boitrel, M.-T., Gulbins, E. & Becker, K.A. Targeting the ceramide system in cancer. Cancer Lett. 332, 286-294 (2013).
10. Ogretmen, B. & Hannun, Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4, 604-616 (2004).
11. Morad, S.A.F. & Cabot, M.C. Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer 13, 51-65 (2013).
12. Kallunki, T., Olsen, O.D. & Jäättelä, M. Cancer-associated lysosomal changes: friends or foes? Oncogene 32, 1995-2004 (2013).
13. Kirkegaard, T. et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 463, 549-553 (2010).
14. Petersen, N.H.T. et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 24, 379-393 (2013).
15. Aits, S. & Jäättelä, M. Lysosomal cell death at a glance. J. Cell Sci. 126, 1905-1912 (2013).
16. Ellegaard, A.-M. et al. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol. Cancer Ther. 12, 2018-2030 (2013).
17. Chipuk, J.E. et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 148, 988-1000 (2012).
18. Tafesse, F.G. et al. Sphingomyelin synthase-related protein SMSr is a suppressor of ceramide-induced mitochondrial apoptosis. J. Cell Sci. 127, 445-454 (2014).
19. Lee, H. et al. Mitochondrial ceramide-rich macrodomains functionalize Bax upon irradiation. PLoS ONE 6, e19783 (2011).
20. Swanton, C. et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
21. Li, Y. et al. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res. 71, 7481-7489 (2011).
22. Yang, H. et al. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 294, 236-244 (2010).
23. Li, Y. et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat. Med. 16, 214-218 (2010).
24. Shao, G.-Z. et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22, 5060-5069 (2003).
25. De Ronde, J.J. et al. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer. Breast Cancer Res. Treat. 137, 213-223 (2013).
26. Hogue, D.L., Ellison, M.J., Young, J.D. & Cass, C.E. Identification of a novel membrane transporter associated with intracellular membranes by phenotypic complementation in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 271, 9801-9808 (1996).
27. Hogue, D.L., Kerby, L. & Ling, V. A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J. Biol. Chem. 274, 12877-12882 (1999).
28. Cabrita, M.A., Hobman, T.C., Hogue, D.L., King, K.M. & Cass, C.E. Mouse transporter protein, a membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. Cancer Res. 59, 4890-4897 (1999).
29. Li, L. et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 29, 5785-5795 (2010).
30. Tan, X. et al. LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. EMBO J. 34, 475-490 (2015).
31. Tan, X., Thapa, N., Sun, Y. & Anderson, R.A.A. Kinase-Independent Role for EGF Receptor in Autophagy Initiation. Cell 160, 145-160 (2015).
32. Vergarajauregui, S., Martina, J.A. & Puertollano, R. LAPTMs regulate lysosomal function and interact with mucolipin 1: new clues for understanding mucolipidosis type IV. J. Cell Sci. 124, 459-468 (2011).
33. Pietiäinen, V. et al. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. J. Cell Sci. 126, 3961-3971 (2013).
34. Shen, D. et al. Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat. Commun. 3, 731 (2012).
35. Wegner, C.S. et al. Ultrastructural characterization of giant endosomes induced by GTPase-deficient Rab5. Histochem. Cell Biol. 133, 41-55 (2010).
36. Reynolds, C.P., Maurer, B.J. & Kolesnick, R.N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 206, 169-180 (2004).
37. Ji, C. et al. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 29, 6557-6568 (2010).
38. Bedia, C., Casas, J., Andrieu-Abadie, N., Fabriàs, G. & Levade, T. Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine. J. Biol. Chem. 286, 28200-28209 (2011).
39. Ullio, C. et al. Sphingosine mediates TNFα-induced lysosomal membrane permeabilization and ensuing programmed cell death in hepatoma cells. J. Lipid Res. 53, 1134-1143 (2012).
40. Heinrich, M. et al. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death Differ. 11, 550-563 (2004).
41. Heinrich, M. et al. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 18, 5252-5263 (1999).
42. Ostenfeld, M.S. et al. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 65, 8975-8983 (2005).
43. Sandhoff, K. My journey into the world of sphingolipids and sphingolipidoses. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 88, 554-582 (2012).
44. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244-1247 (2008).
45. Contreras, F.-X. et al. Molecular recognition of a single sphingolipid species by a protein's transmembrane domain. Nature 481, 525-529 (2012).
46. Björkholm, P. et al. Identification of novel sphingolipid-binding motifs in mammalian membrane proteins. Biochim. Biophys. Acta 1838, 2066-2070 (2014).
47. Juul, N. et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 11, 358-365 (2010).
48. Lee, A.J.X. et al. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J. Pathol. 226, 482-494 (2012).
49. Bandhuvula, P., Li, Z., Bittman, R. & Saba, J.D. Sphingosine 1-phosphate lyase enzyme assay using a BODIPY-labeled substrate. Biochem. Biophys. Res. Commun. 380, 366-370 (2009).
50. Loizides-Mangold, U., David, F.P.A., Nesatyy, V.J., Kinoshita, T. & Riezman, H. Glycosylphosphatidylinositol anchors regulate glycosphingolipid levels. J. Lipid Res. 53, 1522-1534 (2012).
51. Sullards, M.C. & Merrill, A.H. Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Sci. STKE 2001, pl1 (2001).